0001564590-21-041673 | 10-Q | XBRL Viewer | Intellia Therapeutics INC

Collaborations (Tables)

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Changes in Accounts Receivable and Contract Liabilities

The following table presents changes in the Company’s accounts receivable and contract liabilities during the six months ended June 30, 2021 and 2020 (in thousands):

	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Six Months Ended June 30, 2021
Accounts receivable	$	2,130	$	3,079	$	(3,216	)	$	1,993
Contract liabilities - Deferred revenue	$	73,931	$	-	$	(11,179	)	$	62,752

	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Six Months Ended June 30, 2020
Accounts receivable	$	4,620	$	101,049	$	(101,805	)	$	3,864
Contract liabilities - Deferred revenue	$	28,810	$	87,477	$	(15,608	)	$	100,679

Summary of Revenues Recognized Resulting From Changes in Contract Liability Balance

During the six months ended June 30, 2021 and 2020, the Company recognized the following revenues as a result of changes in the contract liability balance (in thousands):

	Six Months Ended June 30,
Revenue recognized in the period from:		2021		2020
Amounts included in the contract liability at the beginning of the period	$	11,179	$	5,674

Subsequent Events - Additional Information (Detail)				1 Months Ended	6 Months Ended	74 Months Ended
Subsequent Events - Additional Information (Detail)	Jul. 02, 2021 USD ($)	Jun. 29, 2021 $ / shares shares	Jun. 22, 2021 USD ($)	Jul. 31, 2021 ft² USD_per_sqft	Jun. 30, 2021	Jun. 30, 2021 USD ($)
Subsequent Event [Line Items]
Proceeds from common stock offering						$ 1,166,100,000
17 Tudor Lease [Member]
Subsequent Event [Line Items]
Term of lease					5 years	5 years
Operating lease, description					In July 2021, the Company entered into an agreement to lease approximately 13,662 square feet of space at 17 Tudor Street in Cambridge, Massachusetts under an operating lease agreement (the “17 Tudor Lease”). The Company’s obligation to pay rent will start on November 1, 2021.
Operating lease, options to extend					The Company has an option to extend the 17 Tudor Lease for one three-year term.
Operating lease, existence of option to extend					true
Subsequent Event [Member] \| 17 Tudor Lease [Member]
Subsequent Event [Line Items]
Area of space leased \| ft²				13,662
Base rent per square foot for first year \| USD_per_sqft				74.00
Base rent per square foot for last year \| USD_per_sqft				83.29
New CAR T-Cell Therapy [Member] \| Maximum [Member] \| Blackstone Life Sciences [Member]
Subsequent Event [Line Items]
Fund amount committed			$ 250,000,000
Underwriting Agreement [Member] \| July 2021 Offering [Member]
Subsequent Event [Line Items]
Number of common stock issued upon conversion of shares \| shares		4,758,620
Public offering price per share \| $ / shares		$ 145.00
Underwriting Agreement [Member] \| Subsequent Event [Member] \| July 2021 Offering [Member]
Subsequent Event [Line Items]
Proceeds from common stock offering	$ 648,100,000
Underwriting discounts and estimated offering costs	$ 41,900,000

Loss Per Share - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share (Detail) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	7,761	7,829
RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	497	248
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential dilutive securities excluded from computation of diluted net loss per common share	7,264	7,581

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Summary of Financial Assets Recognized at Fair Value on Recurring Basis

As of June 30, 2021 and December 31, 2020, the Company’s financial assets recognized at fair value on a recurring basis consisted of the following:

	Fair Value as of June 30, 2021
	Total		Level 1		Level 2		Level 3
	(In thousands)
Cash equivalents and restricted cash equivalents	$	130,005	$	130,005	$	-	$	-
Marketable securities:
U.S. Treasury and other government securities		163,852		140,494		23,358		-
Financial institution debt securities		182,041		-		182,041		-
Corporate debt securities		42,193		-		42,193		-
Other asset-backed securities		33,316		-		33,316		-
Total marketable securities		421,402		140,494		280,908		-
Total	$	551,407	$	270,499	$	280,908	$	-

	Fair Value as of December 31, 2020
	Total		Level 1		Level 2		Level 3
	(In thousands)
Cash equivalents and restricted cash equivalents	$	163,805	$	163,805	$	-	$	-
Marketable securities:
U.S. Treasury and other government securities		245,668		241,664		4,004		-
Financial institution debt securities		138,443		-		138,443		-
Corporate debt securities		41,766		-		41,766		-
Other asset-backed securities		11,474		-		11,474		-
Total marketable securities		437,351		241,664		195,687		-
Total	$	601,156	$	405,469	$	195,687	$	-

Equity-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining vesting period	4 years
Weighted Average Grant Date Fair Value per Share, Granted				$ 62.82
Number of Shares, Granted				353,072
Additional vesting of shares				26,235
Unrecognized equity-based compensation expense related to restricted stock		$ 22.8		$ 22.8
Weighted average grant date fair value per share		$ 48.44	$ 9.04	$ 38.70	$ 8.16
Total intrinsic value of stock options exercised		$ 29.7	$ 0.5	$ 84.5	$ 0.8
Unrecognized compensation cost related to stock options		$ 91.6		$ 91.6
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value per Share, Granted	$ 57.71
Number of Shares, Granted	259,839
Weighted average period of unrecognized compensation costs				3 years 1 month 6 days
RSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining vesting period				1 year 6 months
Weighted Average Grant Date Fair Value per Share, Granted				$ 15.05
Number of Shares, Granted				78,705
Additional vesting of shares				26,235
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average period of unrecognized compensation costs				3 years 1 month 6 days
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining vesting period				3 years
Description of stock options granted under the Plan				Stock options granted under the 2015 Plan generally vest 25% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining three years, unless they contain specific performance-based vesting provisions. The maximum term of stock options granted under the 2015 Plan is ten years.
2015 Plan [Member] \| First Anniversary of Original Vesting Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vest percentage on the first anniversary				25.00%
2015 Plan and the 2016 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future issuance		3,938,391		3,938,391
Percentage of cumulative increase in number of shares for future issuance				4.00%
2016 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future issuance		500,000		500,000
Percentage of cumulative increase in number of shares for future issuance				1.00%
Maximum [Member] \| 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum term of stock options granted				10 years

Related Party Transactions

6 Months Ended

Jun. 30, 2021

Related Party Transactions

12.	Related Party Transactions

In the ordinary course of business, the Company may purchase materials or supplies from entities that are associated with a party that meets the criteria of a related party of the Company. These transactions are reviewed quarterly and to date have not been material to the Company’s condensed consolidated financial statements.

Collaborations - Summary of Revenues Recognized Resulting From Changes in Contract Liability Balance (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Amounts included in the contract liability at the beginning of the period	$ 11,179	$ 5,674

Equity-Based Compensation

6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity-Based Compensation

9.	Equity-Based Compensation

In April 2016, the Company adopted the Amended and Restated 2015 Stock Option and Incentive Plan (the “2015 Plan”). The 2015 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units (“RSUs”) and other stock-based awards. Recipients of incentive stock options and non-qualified stock options are eligible to purchase shares of the Company’s common stock at an exercise price equal to the fair value of such stock on the grant date. Stock options granted under the 2015 Plan generally vest 25% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining three years, unless they contain specific performance-based vesting provisions. The maximum term of stock options granted under the 2015 Plan is ten years.

As of June 30, 2021, there were 3,938,391 shares available for future issuance under the 2015 Plan and the 2016 Employee Stock Purchase Plan. The number of shares reserved for issuance under the 2015 Plan shall be cumulatively increased by four percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of common stock as determined by the board of directors. The number of shares reserved for issuance under the 2016 Employee Stock Purchase Plan shall be cumulatively increased by the lesser of a) one percent of the number of shares of common stock issued and outstanding on the immediately preceding December 31, b) 500,000 shares of common stock, or c) such lesser number of shares of common stock as determined by the board of directors.

Equity-based compensation expense is classified in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	(In thousands)
Research and development	$	6,135	$	2,390	$	9,626	$	4,550
General and administrative		4,479		2,374		7,412		4,371
Total	$	10,614	$	4,764	$	17,038	$	8,921

Restricted Stock Units

Restricted stock units are measured at fair value based on the quoted price of the Company’s common stock.

The following table summarizes the Company’s restricted stock activity for the six months ended June 30, 2021:

	Number of Shares			Weighted Average Grant Date Fair Value per Share
Unvested restricted stock units as of December 31, 2020		193,936		$	23.98
Granted		353,072			62.82
Vested		(26,235	)		15.05
Cancelled		(23,588	)		38.90
Unvested restricted stock units as of June 30, 2021		497,185		$	51.33

In March 2021, the Company granted 259,839 RSUs with a service condition to executive and non-executive employees as part of their annual grant, which vest over a period of four years. The weighted average grant date fair value of these RSUs was $57.71. The vesting start date for these RSUs is January 1, 2021.

Included in the unvested restricted stock as of June 30, 2021 are 78,705 RSUs that include a performance condition in addition to a service condition. These RSUs will vest over a period of 1.5 years and are subject to accelerated vesting based on the Company’s programs achieving certain development milestones before December 1, 2022. The fair value of the RSUs at date of grant was $15.05. An additional 26,235 shares from this grant vested in the six months ended June 30, 2021, as a service condition had been reached.

As of June 30, 2021, there was $22.8 million of unrecognized equity-based compensation expense related to restricted stock that is expected to vest. These costs are expected to be recognized over a weighted average remaining vesting period of 3.1 years.

Stock Options

The weighted average grant date fair value of options, estimated as of the grant date using the Black-Scholes option pricing model, was $48.44 and $38.70 per option for those options granted during the three and six months ended June 30, 2021 and $9.04 and $8.16 per option for those options granted during the three and six months ended June 30, 2020, respectively. The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the three and six months ended June 30, 2021 was $29.7 million and $84.5 million, respectively, and during the three and six months ended June 30, 2020 was $0.5 million and $0.8 million, respectively. Weighted average assumptions used to apply this pricing model were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,
	2021	2020	2021	2020
Risk-free interest rate	1.1%	0.4%	0.9%	0.9%
Expected life of options	6.0 years	5.5-6.0 years	6.0 years	5.5-6.0 years
Expected volatility of underlying stock	73.0%	70.2%	72.2%	67.3%
Expected dividend yield	0.0%	0.0%	0.0%	0.0%

Risk-free Interest Rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant with maturities approximately equal to the option’s expected term.

Expected Dividend Yield. The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends.

Expected Volatility. The expected volatility was derived from a blend of the Company’s historical volatility and an average of the historical stock volatilities of several peer companies within the Company’s industry, both over a period equivalent to the expected term of the stock option grants.

Expected Term. The expected term represents the period that stock option awards are expected to be outstanding. For option grants that are considered to be “plain vanilla,” the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate the expected term.

The Company uses the market closing price of its common stock as reported on the Nasdaq Global Select Market to determine the fair value of the shares of common stock underlying stock options. The following is a summary of stock option activity for the six months ended June 30, 2021:

	Number of Options			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
						(In years)		(In thousands)
Outstanding at December 31, 2020		6,977,440		$	15.43
Granted		1,993,802			61.07
Exercised		(1,409,370	)		13.84
Forfeited		(298,214	)		27.85
Outstanding at June 30, 2021		7,263,658		$	27.75		8.14	$	974,470
Exercisable at June 30, 2021		2,815,568

As of June 30, 2021, there was $91.6 million of unrecognized compensation cost related to stock options that have not yet vested. These costs are expected to be recognized over a weighted average remaining vesting period of 3.1 years.

Marketable Securities - Additional Information (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Realized gains or losses on marketable securities	$ 0	$ 0
Investments that matured beyond five years	$ 0	$ 0
Minimum [Member]
Marketable Securities [Line Items]
Available-for-sales Securities, non-current, maturity period	1 year
Maximum [Member]
Marketable Securities [Line Items]
Available-for-sales Securities, non-current, maturity period	5 years

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	6 Months Ended		74 Months Ended
	Aug. 31, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021
Class Of Stock [Line Items]
Proceeds from common stock offering				$ 1,166.1
2019 Sales Agreement [Member]
Class Of Stock [Line Items]
Proceeds from common stock offering		$ 45.3	$ 14.7
Percentage of gross proceeds from common stock as sales agent cash commission		3.00%
Number of common stock issued upon conversion of shares		641,709	1,107,100
Common stock price per share		$ 72.79	$ 13.78	$ 72.79
Proceeds from common stock offering		$ 47.4		$ 47.4
2019 Sales Agreement [Member] \| General and Administrative Expenses [Member]
Class Of Stock [Line Items]
Legal accounting and other fees		$ 0.1	$ 0.1
2019 Sales Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Proceeds from common stock offering	$ 150.0

Commitments and Contingencies

6 Months Ended

Jun. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

6.	Commitments and Contingencies

Litigation

There have been no material changes to any of the outstanding litigation, nor is the Company a party to any new litigation, since December 31, 2020, except as described below. For further information please see the notes to the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2020.

Caribou Arbitration

On October 17, 2018, the Company initiated an arbitration proceeding against Caribou Biosciences, Inc. (“Caribou”) asserting that Caribou violated the terms and conditions of a license agreement the Company entered into with them in July 2014 related to certain IP (the “Caribou License”), as well as other contractual and legal obligations to the Company, by using and seeking to license to third parties two patent families relating to specific structural or chemical modifications of guide RNAs (“gRNAs”), that were purportedly invented or controlled by Caribou, in the Company’s exclusive human therapeutic field, before an agreed-upon cutoff date of January 30, 2018.

On September 26, 2019, the Company announced that the arbitration panel issued an interim award concluding that both the structural and chemical gRNA modification technologies were exclusively licensed to the Company by Caribou pursuant to the Caribou License. Nevertheless, the arbitration panel, solely with respect to the clinically modified gRNAs, stated that it will declare that Caribou has an equitable “leaseback”, which it described as exclusive, perpetual and worldwide (the “Caribou Award”). The Caribou Award does not include the structural guide modifications IP also at issue in the arbitration, any other IP exclusively licensed or sublicensed by Caribou to the Company under the Caribou License (including but not limited to the foundational CRISPR/Cas9 IP co-owned by the Regents of the University of California, University of Vienna and Dr. Emmanuelle Charpentier), or any other of the Company’s IP. On February 6, 2020, the panel clarified that the Caribou Award is limited to a particular on-going Caribou program, known as CB-010, which seeks to develop a chimeric antigen receptor T (“CAR-T”) product directed at CD19.

On June 16, 2021, the Company executed a Leaseback Agreement (“Leaseback”) with Caribou, which settles the ongoing arbitration. Under the Leaseback negotiated by the parties, in exchange for an upfront payment, potential future regulatory and sales milestones, and single-digit royalties payable by Caribou, the Company has agreed to leaseback or sublicense certain CRISPR/Cas9 IP, including the Company’s chemical gRNA modification technology and foundational CRISPR/Cas9 IP, to Caribou so that it can develop and commercialize CB-010. Caribou also will be responsible for any payments required in respect of the Company’s in-licensed IP. The Company recorded $1.0 million within “Collaboration Revenue” on the condensed consolidated statements of operations and comprehensive loss for an upfront payment related to the Leaseback.

License Agreements

The Company is party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2021, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued research and development	$ 18,399	$ 11,008
Employee compensation and benefits	10,039	10,920
Accrued legal and professional expenses	4,109	1,876
Accrued other	4,603	1,750
Total accrued expenses	$ 37,150	$ 25,554

Collaborations - Summary of Changes in Accounts Receivable and Contract Liabilities (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Accounts receivable:
Accounts receivable, Balance at Beginning of Period	$ 2,130	$ 4,620
Accounts receivable, Additions	3,079	101,049
Accounts receivable, Deductions	(3,216)	(101,805)
Accounts receivable, Balance at End of Period	1,993	3,864
Contract liabilities:
Deferred revenue, Balance at Beginning of Period	73,931	28,810
Deferred revenue, Additions		87,477
Deferred revenue, Deductions	(11,179)	(15,608)
Deferred revenue, Balance at End of Period	$ 62,752	$ 100,679

Overview and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	6 Months Ended		74 Months Ended
	Jul. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from common stock offering				$ 1,166,100
Proceeds from issuance of convertible preferred stock				85,000
Collaborative Arrangement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from common stock offering				275,900
Initial Public Offering and Concurrent Private Placements [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from common stock offering				170,500
Follow-on public Offerings [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from common stock offering			$ 107,732	438,300
At The Market Offerings [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from common stock offering		$ 45,255	$ 14,722	$ 196,500
Underwritten Public Offering [Member] \| Subsequent Event [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from common stock offering	$ 648,100
Number of common stock issued upon conversion of shares	4,758,620
Public offering price per share	$ 145.00
Underwriting discounts and estimated offering costs	$ 41,900

Accrued Expenses

6 Months Ended

Jun. 30, 2021

Payables And Accruals [Abstract]

Accrued Expenses

5.	Accrued Expenses

Accrued expenses consisted of the following:

	June 30,		December 31,
	2021		2020
	(In thousands)
Accrued research and development	$	18,399	$	11,008
Employee compensation and benefits		10,039		10,920
Accrued legal and professional expenses		4,109		1,876
Accrued other		4,603		1,750
Total accrued expenses	$	37,150	$	25,554

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2021

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consisted of the following:

	June 30,		December 31,
	2021		2020
	(In thousands)
Accrued research and development	$	18,399	$	11,008
Employee compensation and benefits		10,039		10,920
Accrued legal and professional expenses		4,109		1,876
Accrued other		4,603		1,750
Total accrued expenses	$	37,150	$	25,554

Equity-Based Compensation - Schedule of Equity-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 10,614	$ 4,764	$ 17,038	$ 8,921
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	6,135	2,390	9,626	4,550
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Equity-based compensation expense	$ 4,479	$ 2,374	$ 7,412	$ 4,371

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 129,879	$ 160,020
Marketable securities	399,140	437,351
Accounts receivable	1,993	2,130
Prepaid expenses and other current assets	18,392	17,016
Total current assets	549,404	616,517
Marketable securities - noncurrent	22,262
Property and equipment, net	18,530	15,943
Operating lease right-of-use assets	77,070	39,114
Other assets	4,977	4,748
Total Assets	672,243	676,322
Current Liabilities:
Accounts payable	6,854	10,460
Accrued expenses	37,150	25,554
Current portion of operating lease liability	7,415	5,696
Current portion of deferred revenue	22,544	22,544
Total current liabilities	73,963	64,254
Deferred revenue, net of current portion	40,208	51,387
Long-term operating lease liability	63,259	33,609
Commitments and contingencies (Note 6)
Stockholders’ Equity:
Common stock, $0.0001 par value; 120,000,000 shares authorized; 68,331,780 and 66,234,056 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	7	7
Additional paid-in capital	1,044,939	962,173
Accumulated other comprehensive (loss) income	(13)	1
Accumulated deficit	(550,120)	(435,109)
Total stockholders’ equity	494,813	527,072
Total Liabilities and Stockholders’ Equity	$ 672,243	$ 676,322

Equity-Based Compensation - Summary of Restricted Stock Activity (Detail)	6 Months Ended
	Jun. 30, 2021 $ / shares shares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Unvested, Beginning balance \| shares	193,936
Number of Shares, Granted \| shares	353,072
Number of Shares, Vested \| shares	(26,235)
Number of Shares, Cancelled \| shares	(23,588)
Number of Shares, Unvested, Ending balance \| shares	497,185
Weighted Average Grant Date Fair Value per Share, Unvested, Beginning balance \| $ / shares	$ 23.98
Weighted Average Grant Date Fair Value per Share, Granted \| $ / shares	62.82
Weighted Average Grant Date Fair Value per Share, Vested \| $ / shares	15.05
Weighted Average Grant Date Fair Value per Share, Cancelled \| $ / shares	38.90
Weighted Average Grant Date Fair Value per Share, Unvested, Ending balance \| $ / shares	$ 51.33

Collaborations - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		63 Months Ended
	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		$ 6,550,000	$ 16,263,000	$ 12,995,000	$ 29,179,000
Deferred revenue		62,752,000	100,679,000	62,752,000	100,679,000	$ 62,752,000	$ 73,931,000	$ 28,810,000
Caribou [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment				1,000,000.0
Regeneron [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment				1,000,000.0
Regeneron Pharmaceuticals Inc. [Member] \| Regeneron Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Deferred revenue additions						145,000,000.0
Collaboration revenue		5,500,000	1,000,000	$ 12,000,000.0	24,200,000	135,200,000
Aggregate transaction price remaining to be recognized, period				Through June 30, 2021
Payments due		1,000,000.0	$ 3,800,000	$ 1,800,000	$ 8,600,000
Regeneron Pharmaceuticals Inc. [Member] \| Regeneron Agreement [Member] \| Research and Development Services [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue						35,600,000
Regeneron Pharmaceuticals Inc. [Member] \| Regeneron Amendment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate transaction price remaining to be recognized		62,800,000		62,800,000		62,800,000
Accounts receivable		1,000,000.0		1,000,000.0		1,000,000.0	2,100,000
Deferred revenue		62,800,000		$ 62,800,000		62,800,000	73,900,000
Regeneron Pharmaceuticals Inc. [Member] \| Hemophilia Co/Co Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue		1,000,000.0
Novartis [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Strategic collaboration agreement amended date				2018-12
One time payment to novartis		10,000,000.0		$ 10,000,000.0
Novartis [Member] \| Regeneron Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue	$ 5,000,000.0
Deferred revenue		0		0		0	0
Accounts receivable		$ 0		$ 0		$ 0	$ 0

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2021

Investments Debt And Equity Securities [Abstract]

Summary of Available-for-sale Marketable Securities

The following table summarizes the Company’s available-for-sale marketable securities as of June 30, 2021 and December 31, 2020 at net book value:

	June 30, 2021
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	(In thousands)
Marketable securities:
U.S. Treasury and other government securities	$	163,832	$	22	$	(2	)	$	163,852
Financial institution debt securities		182,076		12		(47	)		182,041
Corporate debt securities		42,191		2		-			42,193
Other asset-backed securities		33,315		1		-			33,316
Total	$	421,414	$	37	$	(49	)	$	421,402

	December 31, 2020
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	(In thousands)
Marketable securities:
U.S. Treasury and other government securities	$	245,666	$	13	$	(11	)	$	245,668
Financial institution debt securities		138,445		6		(8	)		138,443
Corporate debt securities		41,765		3		(2	)		41,766
Other asset-backed securities		11,474		1		(1	)		11,474
Total	$	437,350	$	23	$	(22	)	$	437,351

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended		74 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (115,011)	$ (64,199)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	3,225	3,107
Equity-based compensation	17,038	8,921
Amortization/(accretion) of investment premiums/(discounts)	2,868	(268)
Changes in operating assets and liabilities:
Accounts receivable	137	756
Prepaid expenses and other current assets	(8,703)	(564)
Operating right-of-use assets	4,018	3,195
Other assets	(229)	239
Accounts payable	(2,606)	(3,899)
Accrued expenses	10,135	2,434
Deferred revenue	(11,179)	71,869
Operating lease liabilities	(5,050)	(2,719)
Net cash (used in) provided by operating activities	(105,357)	18,872
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(5,350)	(1,881)
Purchases of marketable securities	(185,431)	(31,208)
Maturities of marketable securities	198,499	183,500
Net cash provided by investing activities	7,718	150,411
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock			$ 1,166,100
Proceeds from options exercised	19,503	1,370
Issuance of shares through employee stock purchase plan	970	685
Net cash provided by financing activities	65,728	137,089
Net (decrease) increase in cash and cash equivalents and restricted cash and cash equivalents	(31,911)	306,372
Cash and cash equivalents and restricted cash and cash equivalents, beginning of period	164,606	57,226
Cash and cash equivalents and restricted cash and cash equivalents, end of period	132,695	363,598	132,695
Reconciliation of cash and cash equivalents and restricted cash and cash equivalents to condensed consolidated balance sheet:
Cash and cash equivalents	129,879	361,687	129,879
Restricted cash and cash equivalents, included in prepaids and other current assets and other assets	2,816	1,911	2,816
Cash and cash equivalents and restricted cash and cash equivalents, end of period	132,695	363,598	132,695
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Purchases of property and equipment unpaid at period end	1,969	432
Right-of-use assets acquired under operating leases	41,974	7,527
Offering costs unpaid at period end	208
Follow-on Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		107,732	438,300
At The Market Offerings [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	$ 45,255	14,722	$ 196,500
Regeneron Pharmaceuticals Inc. [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		$ 12,580

Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Net loss	$ (68,806)	$ (46,205)	$ (32,393)	$ (31,806)	$ (115,011)	$ (64,199)
Weighted average shares outstanding, basic and diluted	68,164		53,369		67,675	51,938
Net loss per share, basic and diluted	$ (1.01)		$ (0.61)		$ (1.70)	$ (1.24)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	68,331,780	66,234,056
Common stock, shares outstanding	68,331,780	66,234,056

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Jul. 30, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	NTLA
Entity Registrant Name	INTELLIA THERAPEUTICS, INC.
Entity Central Index Key	0001652130
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		73,487,046
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity File Number	001-37766
Entity Tax Identification Number	36-4785571
Entity Address, Address Line One	40 Erie Street
Entity Address, Address Line Two	Suite 130
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02139
City Area Code	857
Local Phone Number	285-6200
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false

Leases

6 Months Ended

Jun. 30, 2021

Leases [Abstract]

Leases

In March 2020, the Company entered into an agreement to lease approximately 39,000 square feet of office and laboratory space at 281 Albany Street in Cambridge, Massachusetts under an operating lease agreement (the “281 Albany Lease”). The Company’s obligation to pay rent will start on the date that is six months after the commencement date or the date on which the Company occupies the premises, whichever occurs earlier (the “Rent Commencement Date”). The initial term of the 281 Albany Lease is ten years following the Rent Commencement Date. In March 2021 the Company determined, in accordance with Accounting Standards Codification 842, “Leases (Topic 842)”, that the commencement date of the lease had been met as the facility was substantially complete and available for use and, accordingly, the Company recognized a right-of-use asset and a lease liability of approximately $40.4 million and $34.8 million, respectively, in the first quarter of 2021 related to the 281 Albany Lease. In determining the lease liability, the Company used an incremental borrowing rate of 5.52% based on a number of factors including the total lease payments, the Company’s credit rating, and the lease term. Included in the recognized right-of-use asset at the inception of the lease was approximately $5.6 million in lease payments that were prepaid under the terms of the lease. The base rent under the 281 Albany Lease is $99.00 per square foot per year during the first year of the term, which is subject to scheduled annual increases up to $128.87 per square foot per year during the last year of the initial term, plus certain operating expenses and taxes. In addition, the landlord agreed to contribute an aggregate of $4.4 million toward the cost of construction and tenant improvements for the premises. In accordance with the 281 Albany Lease, the Company is required to maintain a letter of credit in the amount of $1.9 million that is restricted for the term of the lease. These restricted cash equivalents are reported in “Other Assets” in the Company’s condensed consolidated balance sheets. The Company has the option to extend the 281 Albany Lease for two successive five-year terms. The option for this extension is not included as part of the lease liability and right-of-use asset at June 30, 2021, as it is not reasonably certain that it will be exercised.

Fair Value Measurements - Summary of Financial Assets Recognized at Fair Value on Recurring Basis (Detail) - Fair Value on Recurring Basis [Member] - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents and restricted cash equivalents	$ 130,005	$ 163,805
Marketable securities:
Marketable securities	421,402	437,351
Total	551,407	601,156
U.S. Treasury and Other Government Securities [Member]
Marketable securities:
Marketable securities	163,852	245,668
Financial Institution Debt Securities [Member]
Marketable securities:
Marketable securities	182,041	138,443
Corporate Debt Securities [Member]
Marketable securities:
Marketable securities	42,193	41,766
Other Asset Backed Securities [Member]
Marketable securities:
Marketable securities	33,316	11,474
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents and restricted cash equivalents	130,005	163,805
Marketable securities:
Marketable securities	140,494	241,664
Total	270,499	405,469
Level 1 [Member] \| U.S. Treasury and Other Government Securities [Member]
Marketable securities:
Marketable securities	140,494	241,664
Level 2 [Member]
Marketable securities:
Marketable securities	280,908	195,687
Total	280,908	195,687
Level 2 [Member] \| U.S. Treasury and Other Government Securities [Member]
Marketable securities:
Marketable securities	23,358	4,004
Level 2 [Member] \| Financial Institution Debt Securities [Member]
Marketable securities:
Marketable securities	182,041	138,443
Level 2 [Member] \| Corporate Debt Securities [Member]
Marketable securities:
Marketable securities	42,193	41,766
Level 2 [Member] \| Other Asset Backed Securities [Member]
Marketable securities:
Marketable securities	$ 33,316	$ 11,474

Stockholders’ Equity

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Stockholders’ Equity

11.	Stockholders’ Equity

The following tables present changes in stockholders’ equity for the six-month periods ended June 30, 2021 and 2020 (in thousands, except share data):

					Additional		Accumulated Other						Total
	Common				Paid-In		Comprehensive			Accumulated			Stockholders’
	Shares		Amount		Capital		Income (Loss)			Deficit			Equity
Balance at December 31, 2020		66,234,056	$	7	$	962,173	$	1		$	(435,109	)	$	527,072
Issuance of common stock through at-the-market offerings, net of issuance costs of $52		641,709		-		45,255		-			-			45,255
Exercise of stock options		1,014,569		-		13,340		-			-			13,340
Equity-based compensation		-		-		6,424		-			-			6,424
Other comprehensive loss		-		-		-		(13	)		-			(13	)
Net loss		-		-		-		-			(46,205	)		(46,205	)
Balance at March 31, 2021		67,890,334		7		1,027,192		(12	)		(481,314	)		545,873
Exercise of stock options		394,801		-		6,163		-			-			6,163
Vesting of restricted units		26,235		-		-		-			-			-
Issuance of shares under employee stock purchase plan		20,410		-		970		-			-			970
Equity-based compensation		-		-		10,614		-			-			10,614
Other comprehensive loss		-		-		-		(1	)		-			(1	)
Net loss		-		-		-		-			(68,806	)		(68,806	)
Balance at June 30, 2021		68,331,780	$	7	$	1,044,939	$	(13	)	$	(550,120	)	$	494,813

					Additional		Accumulated Other						Total
	Common				Paid-In		Comprehensive			Accumulated			Stockholders’
	Shares		Amount		Capital		Income			Deficit			Equity
Balance at December 31, 2019		50,198,044	$	5	$	570,493	$	261		$	(300,878	)	$	269,881
Issuance of common stock through at-the-market offerings, net of issuance costs of $48		351,252		-		5,079		-			-			5,079
Exercise of stock options		53,579		-		336		-			-			336
Equity-based compensation		-		-		4,157		-			-			4,157
Other comprehensive income		-		-		-		112			-			112
Net loss		-		-		-		-			(31,806	)		(31,806	)
Balance at March 31, 2020		50,602,875		5		580,065		373			(332,684	)		247,759
Issuance of common stock through follow-on offering, net of issuance costs of $369		6,301,370		1		107,731		-			-			107,732
Issuance of common stock in private placement with Regeneron		925,218		-		12,580		-			-			12,580
Issuance of common stock through at-the-market offerings, net of issuance costs of $23		755,848		-		9,643		-			-			9,643
Exercise of stock options		83,631		-		1,035		-			-			1,035
Issuance of shares under employee stock purchase plan		55,296		-		685		-			-			685
Equity-based compensation		-		-		4,764		-			-			4,764
Other comprehensive loss		-		-		-		(218	)		-			(218	)
Net loss		-		-		-		-			(32,393	)		(32,393	)
Balance at June 30, 2020		58,724,238	$	6	$	716,503	$	155		$	(365,077	)	$	351,587

At-the-Market Offering Programs

In August 2019, the Company entered into an Open Market Sale Agreement (the “2019 Sales Agreement”) with Jefferies, under which Jefferies was able to offer and sell, from time to time in “at-the-market” offerings, common stock having aggregate gross proceeds of up to $150.0 million. The Company agreed to pay Jefferies cash commissions of 3.0% of the gross

proceeds of sales of common stock under the 2019 Sales Agreement. Please refer to the Company’s Annual Report for the year ended December 31, 2020 for additional information regarding these offerings.

During the six months ended June 30, 2021, the Company issued 641,709 shares of its common stock in a series of sales at an average price of $72.79 per share in accordance with the 2019 Sales Agreement, for aggregate net proceeds of $45.3 million after payment of cash commissions to Jefferies and approximately $0.1 million related to legal, accounting and other fees in connection with the sales. During the six months ended June 30, 2020, the Company issued 1,107,100 shares of its common stock in a series of sales at an average price of $13.78 per share in accordance with the 2019 Sales Agreement, for aggregate net proceeds of $14.7 million after payment of cash commissions to Jefferies and approximately $0.1 million related to legal, accounting and other fees in connection with the sales.

As of June 30, 2021, $47.4 million in shares of common stock remain eligible for sale under the 2019 Sales Agreement.

Stockholders’ Equity (Tables)

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Schedule of Changes in Stockholders’ Equity

The following tables present changes in stockholders’ equity for the six-month periods ended June 30, 2021 and 2020 (in thousands, except share data):

					Additional		Accumulated Other						Total
	Common				Paid-In		Comprehensive			Accumulated			Stockholders’
	Shares		Amount		Capital		Income (Loss)			Deficit			Equity
Balance at December 31, 2020		66,234,056	$	7	$	962,173	$	1		$	(435,109	)	$	527,072
Issuance of common stock through at-the-market offerings, net of issuance costs of $52		641,709		-		45,255		-			-			45,255
Exercise of stock options		1,014,569		-		13,340		-			-			13,340
Equity-based compensation		-		-		6,424		-			-			6,424
Other comprehensive loss		-		-		-		(13	)		-			(13	)
Net loss		-		-		-		-			(46,205	)		(46,205	)
Balance at March 31, 2021		67,890,334		7		1,027,192		(12	)		(481,314	)		545,873
Exercise of stock options		394,801		-		6,163		-			-			6,163
Vesting of restricted units		26,235		-		-		-			-			-
Issuance of shares under employee stock purchase plan		20,410		-		970		-			-			970
Equity-based compensation		-		-		10,614		-			-			10,614
Other comprehensive loss		-		-		-		(1	)		-			(1	)
Net loss		-		-		-		-			(68,806	)		(68,806	)
Balance at June 30, 2021		68,331,780	$	7	$	1,044,939	$	(13	)	$	(550,120	)	$	494,813

					Additional		Accumulated Other						Total
	Common				Paid-In		Comprehensive			Accumulated			Stockholders’
	Shares		Amount		Capital		Income			Deficit			Equity
Balance at December 31, 2019		50,198,044	$	5	$	570,493	$	261		$	(300,878	)	$	269,881
Issuance of common stock through at-the-market offerings, net of issuance costs of $48		351,252		-		5,079		-			-			5,079
Exercise of stock options		53,579		-		336		-			-			336
Equity-based compensation		-		-		4,157		-			-			4,157
Other comprehensive income		-		-		-		112			-			112
Net loss		-		-		-		-			(31,806	)		(31,806	)
Balance at March 31, 2020		50,602,875		5		580,065		373			(332,684	)		247,759
Issuance of common stock through follow-on offering, net of issuance costs of $369		6,301,370		1		107,731		-			-			107,732
Issuance of common stock in private placement with Regeneron		925,218		-		12,580		-			-			12,580
Issuance of common stock through at-the-market offerings, net of issuance costs of $23		755,848		-		9,643		-			-			9,643
Exercise of stock options		83,631		-		1,035		-			-			1,035
Issuance of shares under employee stock purchase plan		55,296		-		685		-			-			685
Equity-based compensation		-		-		4,764		-			-			4,764
Other comprehensive loss		-		-		-		(218	)		-			(218	)
Net loss		-		-		-		-			(32,393	)		(32,393	)
Balance at June 30, 2020		58,724,238	$	6	$	716,503	$	155		$	(365,077	)	$	351,587

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Recent Accounting Pronouncements - Adopted

Recent Accounting Pronouncements – Adopted

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 on January 1, 2021. The adoption did not have a material effect on the Company’s condensed consolidated financial statements.

Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Loss Per Share

Basic and diluted loss per share was calculated as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
	(In thousands)
Net loss	$	(68,806	)	$	(32,393	)	$	(115,011	)	$	(64,199	)
Weighted average shares outstanding, basic and diluted		68,164			53,369			67,675			51,938
Net loss per share, basic and diluted	$	(1.01	)	$	(0.61	)	$	(1.70	)	$	(1.24	)

Potential Dilutive Securities Excluded from Computation of Diluted Net Loss Per Common Share

The following common stock equivalents were excluded from the calculation of diluted loss per share because their inclusion would have been anti-dilutive:

	Three and Six Months Ended June 30,
	2021		2020
	(In thousands)
Unvested restricted stock units		497		248
Stock options		7,264		7,581
		7,761		7,829

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Collaboration revenue	$ 6,550	$ 16,263	$ 12,995	$ 29,179
Type of Revenue [Extensible List]	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Operating expenses:
Research and development	$ 58,884	$ 37,771	$ 98,160	$ 72,421
General and administrative	16,683	11,526	30,277	22,840
Total operating expenses	75,567	49,297	128,437	95,261
Operating loss	(69,017)	(33,034)	(115,442)	(66,082)
Interest income	211	641	431	1,883
Net loss	$ (68,806)	$ (32,393)	$ (115,011)	$ (64,199)
Net loss per share, basic and diluted	$ (1.01)	$ (0.61)	$ (1.70)	$ (1.24)
Weighted average shares outstanding, basic and diluted	68,164	53,369	67,675	51,938
Other comprehensive loss:
Unrealized loss on marketable securities	$ (1)	$ (218)	$ (14)	$ (106)
Comprehensive loss	$ (68,807)	$ (32,611)	$ (115,025)	$ (64,305)

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies” to the consolidated financial statements included in the Annual Report for the year ended December 31, 2020. There have been no material changes during the six months ended June 30, 2021, other than as noted below.

Recent Accounting Pronouncements – Adopted

Equity-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Outstanding, Beginning Balance	6,977,440
Number of options, Granted	1,993,802
Number of options, Exercised	(1,409,370)
Number of options, Forfeited	(298,214)
Number of Options, Outstanding, Ending Balance	7,263,658
Number of Options, Exercisable	2,815,568
Weighted Average Exercise Price per Share, Outstanding, Beginning Balance	$ 15.43
Weighted Average Exercise Price per Share, Granted	61.07
Weighted Average Exercise Price per Share, Exercised	13.84
Weighted Average Exercise Price per Share, Forfeited	27.85
Weighted Average Exercise Price per Share, Outstanding, Ending Balance	$ 27.75
Weighted Average Remaining Contractual Term, Outstanding	8 years 1 month 20 days
Aggregate Intrinsic Value, Outstanding	$ 974,470

Collaborations

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborations

7.	Collaborations

To accelerate the development and commercialization of CRISPR/Cas9-based products in multiple therapeutic areas, the Company has formed, and intends to seek other opportunities to form, strategic alliances with collaborators who can augment its leadership in CRISPR/Cas9 therapeutic development. As of June 30, 2021, the Company’s accounts receivable is made up of $1.0 million for an upfront payment related to the Leaseback with Caribou (see Note 6) and $1.0 million related to the collaboration with Regeneron, and the Company’s contract liabilities were related to its collaboration with Regeneron.

The following table presents changes in the Company’s accounts receivable and contract liabilities during the six months ended June 30, 2021 and 2020 (in thousands):

	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Six Months Ended June 30, 2021
Accounts receivable	$	2,130	$	3,079	$	(3,216	)	$	1,993
Contract liabilities - Deferred revenue	$	73,931	$	-	$	(11,179	)	$	62,752

	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Six Months Ended June 30, 2020
Accounts receivable	$	4,620	$	101,049	$	(101,805	)	$	3,864
Contract liabilities - Deferred revenue	$	28,810	$	87,477	$	(15,608	)	$	100,679

During the six months ended June 30, 2021 and 2020, the Company recognized the following revenues as a result of changes in the contract liability balance (in thousands):

	Six Months Ended June 30,
Revenue recognized in the period from:		2021		2020
Amounts included in the contract liability at the beginning of the period	$	11,179	$	5,674

Costs to obtain and fulfill a contract

The Company did not incur any expenses to obtain collaboration agreements and costs to fulfill those contracts do not generate or enhance resources of the Company. As such, no costs to obtain or fulfill a contract have been capitalized in any period.

Regeneron Pharmaceuticals, Inc.

License and Collaboration Agreement

In April 2016, the Company entered into a license and collaboration agreement with Regeneron (the “2016 Regeneron Agreement”). The 2016 Regeneron Agreement has two principal components: (i) a product development component under which the parties will research, develop and commercialize CRISPR/Cas-based therapeutic products primarily focused on genome editing in the liver, and (ii) a technology collaboration component, pursuant to which the Company and Regeneron will engage in research-related activities aimed at discovering and developing novel technologies and improvements to CRISPR/Cas technology to enhance the Company’s genome editing platform. Under this agreement, the Company also may access the Regeneron Genetics Center and proprietary mouse models to be provided by Regeneron for a limited number of the Company’s liver programs. At the inception of the 2016 Regeneron Agreement, Regeneron selected the first of its 10 targets, transthyretin (“ATTR”) amyloidosis, which is subject to a co-development and co-promotion agreement between the Company and Regeneron (the “ATTR Co/Co”).

On May 30, 2020, the Company entered into (i) amendment no. 1 (the “2020 Regeneron Amendment”) to the 2016 Regeneron Agreement, (ii) co-development and co-funding agreements for the treatment of hemophilia A and hemophilia B (the “Hemophilia Co/Co”) agreements and (iii) a stock purchase agreement. The collaboration expansion builds upon the jointly developed targeted transgene insertion capabilities designed to durably restore a missing therapeutic protein, and to overcome the limitations of traditional gene therapy. The collaboration was extended until April 2024, at which point Regeneron has an option to renew for an additional two years. The 2020 Regeneron Amendment also grants Regeneron exclusive rights to develop products for five additional in vivo CRISPR/Cas-based therapeutic liver targets and non-exclusive rights to independently develop and commercialize up to 10 ex vivo gene edited products made using certain defined cell types.

Since December 31, 2020, there have been no material changes to the key terms of the 2016 Regeneron Agreement and the 2020 Regeneron Amendment (the “Amended Agreements”). For further information on the terms and conditions of these agreements, please see the notes to the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2020.

Revenue Recognition – Collaboration Revenue. Through June 30, 2021, excluding amounts allocated to Regeneron’s purchase of the Company’s common stock, the Company recorded $145.0 million in upfront payments under the Amended Agreements and $35.6 million for research and development services, primarily under the ATTR Co/Co agreement. Through June 30, 2021, the Company has recognized $135.2 million of collaboration revenue under all arrangements, including $5.5 million and $12.0 million during the three and six months ended June 30, 2021, respectively, and $16.3 million and $24.2 million during the three and six months ended June 30, 2020, respectively, in the condensed consolidated statements of operations and comprehensive loss. This includes $1.0 million and $1.8 million during the three and six months ended June 30, 2021, respectively, and $3.8 million and $8.6 million during the three and six months ended June 30, 2020, respectively, primarily representing payments due from Regeneron pursuant to the ATTR Co/Co agreement. These revenues are offset in part by contra-revenue related to the Hemophilia Co/Co agreements amounting to $1.0 million during the three and six months ended June 30, 2021, respectively.

As of June 30, 2021, there was approximately $62.8 million of the aggregate transaction price of the Amended Agreements remaining to be recognized, which the Company expects to be recognized during the research term through April 2024.

As of June 30, 2021 and December 31, 2020, the Company had accounts receivable of $1.0 million and $2.1 million, respectively, related to the Amended Agreements. The Company had deferred revenue of $62.8 million and $73.9 million as of June 30, 2021 and December 31, 2020, respectively, related to the Amended Agreements.

Novartis Institutes for BioMedical Research, Inc.

In December 2014, the Company entered into a strategic collaboration agreement with Novartis Institutes for BioMedical Research, Inc. (“Novartis”) (the “2014 Novartis Agreement”), primarily focused on the research of new ex vivo CRISPR/Cas9-edited therapies using CAR-T cells and hematopoietic stem cells (“HSCs”). The agreement was amended in December 2018 (the “Novartis Amendment”) to also include research on ocular stem cells (“OSCs”). In December 2019, per the terms of the 2014 Novartis Agreement, the research term ended, although the 2014 Novartis Agreement remains in effect, for which the Company will be eligible to receive milestone and royalty payments in the future. In June 2021, the Company entered into Amendment No. 3 (the “Amendment”) to the 2014 Novartis Agreement. The Amendment amends Novartis’ rights with respect to all of the CAR-T Therapeutic Targets (as defined in the 2014 Novartis Agreement) that Novartis selected under the 2014 Novartis Agreement, including (a) making Novartis’ license non-exclusive for such CAR-T Therapeutic Targets, (b) removing Novartis’ diligence and related reporting obligations for such CAR-T Therapeutic Targets, and (c) refining the scope of Novartis’ sublicense rights for such CAR-T Therapeutic Targets. The Company made a one-time payment to Novartis of $10.0 million within 30 days after the effective date of the Amendment, which was recorded as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2021. Since December 31, 2020, there have been no other material changes to the key terms of the 2014 Novartis Agreement and the Novartis Amendment. For further information on the terms and conditions of these agreements, please see the notes to the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2020.

Revenue Recognition – Milestone. In March 2020, the U.S. Food and Drug Administration (“FDA”) accepted the investigational new drug (“IND”) application submitted by Novartis for a CRISPR/Cas9-based engineered cell therapy for the treatment of sickle cell disease. As a result of meeting this milestone, the Company recognized $5.0 million as collaboration revenue within the condensed consolidated statement of operations and comprehensive loss. No other milestones under the 2014 Novartis Agreement and the Novartis Amendment were achieved during the three or six months ended June 30, 2021 or 2020. The Company is eligible to receive additional downstream success-based milestones and royalties.

As of June 30, 2021 and December 31, 2020, the Company had no accounts receivable or deferred revenue related to the 2014 Novartis Agreement and the Novartis Amendment.

Marketable Securities

6 Months Ended

Jun. 30, 2021

Investments Debt And Equity Securities [Abstract]

Marketable Securities

3.	Marketable Securities

The following table summarizes the Company’s available-for-sale marketable securities as of June 30, 2021 and December 31, 2020 at net book value:

	June 30, 2021
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	(In thousands)
Marketable securities:
U.S. Treasury and other government securities	$	163,832	$	22	$	(2	)	$	163,852
Financial institution debt securities		182,076		12		(47	)		182,041
Corporate debt securities		42,191		2		-			42,193
Other asset-backed securities		33,315		1		-			33,316
Total	$	421,414	$	37	$	(49	)	$	421,402

	December 31, 2020
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
	(In thousands)
Marketable securities:
U.S. Treasury and other government securities	$	245,666	$	13	$	(11	)	$	245,668
Financial institution debt securities		138,445		6		(8	)		138,443
Corporate debt securities		41,765		3		(2	)		41,766
Other asset-backed securities		11,474		1		(1	)		11,474
Total	$	437,350	$	23	$	(22	)	$	437,351

The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity. At June 30, 2021 and December 31, 2020, the balance in the Company’s accumulated other comprehensive (loss) income was composed of activity related to the Company’s available-for-sale marketable securities. There were no realized gains or losses in the six months ended June 30, 2021 or for the year ended December 31, 2020. The Company did not reclassify any amounts out of accumulated other comprehensive (loss) income during this period. The Company did not have any securities in a material unrealized loss position at June 30, 2021 or December 31, 2020.

The Company's available-for-sale securities that are classified as short-term marketable securities in the condensed consolidated balance sheet mature within one year or less as of the balance sheet date. Available-for-sale securities that are classified as noncurrent in the condensed consolidated balance sheet are those that mature after one year but within five years from the balance sheet date and that the Company does not intend to dispose of within the next twelve months. At June 30,

2021 and December 31, 2020, the Company did not hold any investments that matured beyond five years of the balance sheet date.

Loss Per Share

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Loss Per Share

10.	Loss Per Share

The Company calculates basic loss per share by dividing net loss for each respective period by the weighted average number of common shares outstanding for each respective period. The Company computes diluted loss per share after giving consideration to the dilutive effect of stock options and unvested restricted stock that are outstanding during the period, except where such securities would be anti-dilutive.

Basic and diluted loss per share was calculated as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
	(In thousands)
Net loss	$	(68,806	)	$	(32,393	)	$	(115,011	)	$	(64,199	)
Weighted average shares outstanding, basic and diluted		68,164			53,369			67,675			51,938
Net loss per share, basic and diluted	$	(1.01	)	$	(0.61	)	$	(1.70	)	$	(1.24	)

The following common stock equivalents were excluded from the calculation of diluted loss per share because their inclusion would have been anti-dilutive:

	Three and Six Months Ended June 30,
	2021		2020
	(In thousands)
Unvested restricted stock units		497		248
Stock options		7,264		7,581
		7,761		7,829

Fair Value Measurements

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

4.	Fair Value Measurements

The Company classifies fair value-based measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1, quoted market prices (unadjusted) in active markets for identical assets or liabilities; Level 2, observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data; and Level 3, unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

As of June 30, 2021 and December 31, 2020, the Company’s financial assets recognized at fair value on a recurring basis consisted of the following:

	Fair Value as of June 30, 2021
	Total		Level 1		Level 2		Level 3
	(In thousands)
Cash equivalents and restricted cash equivalents	$	130,005	$	130,005	$	-	$	-
Marketable securities:
U.S. Treasury and other government securities		163,852		140,494		23,358		-
Financial institution debt securities		182,041		-		182,041		-
Corporate debt securities		42,193		-		42,193		-
Other asset-backed securities		33,316		-		33,316		-
Total marketable securities		421,402		140,494		280,908		-
Total	$	551,407	$	270,499	$	280,908	$	-

	Fair Value as of December 31, 2020
	Total		Level 1		Level 2		Level 3
	(In thousands)
Cash equivalents and restricted cash equivalents	$	163,805	$	163,805	$	-	$	-
Marketable securities:
U.S. Treasury and other government securities		245,668		241,664		4,004		-
Financial institution debt securities		138,443		-		138,443		-
Corporate debt securities		41,766		-		41,766		-
Other asset-backed securities		11,474		-		11,474		-
Total marketable securities		437,351		241,664		195,687		-
Total	$	601,156	$	405,469	$	195,687	$	-

Certain of the Company’s financial assets, including cash equivalents, restricted cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models and observable market inputs to determine value. After completing its validation procedures, the Company did not adjust or override any fair value measurements provided by the pricing services as of June 30, 2021 or December 31, 2020.

Other financial instruments, including accounts receivable, accounts payable and accrued expense, are carried at cost, which approximates fair value due to the short duration and term to maturity.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Equity-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.10%	0.40%	0.90%	0.90%
Expected life of options	6 years		6 years
Expected volatility of underlying stock	73.00%	70.20%	72.20%	67.30%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options		5 years 6 months		5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options		6 years		6 years

Overview and Basis of Presentation

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Overview and Basis of Presentation

1.	Overview and Basis of Presentation

Intellia Therapeutics, Inc. (“Intellia” or the “Company”) is a leading clinical-stage genome editing company, focused on developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (“DNA”). To fully realize the transformative potential of CRISPR/Cas9, the Company is pursuing two primary approaches. The Company’s in vivo programs use intravenously administered CRISPR as the therapy, in which its proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. The Company’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The Company’s deep scientific, technical and clinical development experience, along with its robust intellectual property (“IP”) portfolio, enables the Company to unlock broad therapeutic applications of CRISPR/Cas9 to create new classes of genetic medicine.

The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K (“Annual Report”) for the year ended December 31, 2020.

The unaudited condensed consolidated financial statements include the accounts of Intellia Therapeutics, Inc. and its wholly owned, controlled subsidiary, Intellia Securities Corp. All intercompany balances and transactions have been eliminated in consolidation. Comprehensive loss is comprised of net loss and unrealized gain/loss on marketable securities.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, research and development expenses and equity-based compensation expense. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances at the time such estimates are made. Actual results could differ from those estimates. The Company periodically reviews its estimates in light of changes in circumstances, facts and experience. The extent of the impact of the coronavirus disease 19 (“COVID-19”) pandemic on the Company’s operational and financial performance will depend on certain developments, including the length and severity of this pandemic, as well as its effect on the Company’s employees, collaborators and vendors, all of which are uncertain and cannot be predicted. The Company cannot reasonably estimate the extent to which the disruption may materially impact its consolidated results of operations or financial position.

The effects of material revisions in estimates are reflected in the condensed consolidated financial statements prospectively from the date of the change in estimate.

In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

Liquidity

Since its inception through June 30, 2021, the Company has raised an aggregate of approximately $1,166.1 million to fund its operations, of which $275.9 million was through its collaboration agreements, $170.5 million was from its initial public offering (“IPO”) and concurrent private placements, $438.3 million was from follow-on public offerings, $196.5 million was from at-the-market offerings and $85.0 million was from the sale of convertible preferred stock. In July 2021, the Company closed an underwritten public offering of 4,758,620 shares of common stock at the public offering price of $145.00 per share, for aggregate estimated net proceeds of $648.1 million after deducting approximately $41.9 million in underwriting discounts

and estimated offering costs (see Note 13 for further details). The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2021, along with the proceeds from the July 2021 public offering of common stock, will enable the Company to fund its ongoing operating expenses and capital expenditure requirements for at least the twelve-month period following the issuance of these condensed consolidated financial statements.

Marketable Securities - Summary of Available -for-sale Marketable Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Marketable Securities [Line Items]
Amortized Cost	$ 421,414	$ 437,350
Gross Unrealized Gains	37	23
Gross Unrealized Losses	(49)	(22)
Estimated Fair Value	421,402	437,351
U.S. Treasury and Other Government Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	163,832	245,666
Gross Unrealized Gains	22	13
Gross Unrealized Losses	(2)	(11)
Estimated Fair Value	163,852	245,668
Financial Institution Debt Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	182,076	138,445
Gross Unrealized Gains	12	6
Gross Unrealized Losses	(47)	(8)
Estimated Fair Value	182,041	138,443
Corporate Debt Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	42,191	41,765
Gross Unrealized Gains	2	3
Gross Unrealized Losses		(2)
Estimated Fair Value	42,193	41,766
Other Asset Backed Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	33,315	11,474
Gross Unrealized Gains	1	1
Gross Unrealized Losses		(1)
Estimated Fair Value	$ 33,316	$ 11,474

Equity-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Equity-Based Compensation Expense

Equity-based compensation expense is classified in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	(In thousands)
Research and development	$	6,135	$	2,390	$	9,626	$	4,550
General and administrative		4,479		2,374		7,412		4,371
Total	$	10,614	$	4,764	$	17,038	$	8,921

Summary of Restricted Stock Activity

The following table summarizes the Company’s restricted stock activity for the six months ended June 30, 2021:

	Number of Shares			Weighted Average Grant Date Fair Value per Share
Unvested restricted stock units as of December 31, 2020		193,936		$	23.98
Granted		353,072			62.82
Vested		(26,235	)		15.05
Cancelled		(23,588	)		38.90
Unvested restricted stock units as of June 30, 2021		497,185		$	51.33

Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted

Weighted average assumptions used to apply this pricing model were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,
	2021	2020	2021	2020
Risk-free interest rate	1.1%	0.4%	0.9%	0.9%
Expected life of options	6.0 years	5.5-6.0 years	6.0 years	5.5-6.0 years
Expected volatility of underlying stock	73.0%	70.2%	72.2%	67.3%
Expected dividend yield	0.0%	0.0%	0.0%	0.0%

Summary of Stock Option Activity

The following is a summary of stock option activity for the six months ended June 30, 2021:

	Number of Options			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
						(In years)		(In thousands)
Outstanding at December 31, 2020		6,977,440		$	15.43
Granted		1,993,802			61.07
Exercised		(1,409,370	)		13.84
Forfeited		(298,214	)		27.85
Outstanding at June 30, 2021		7,263,658		$	27.75		8.14	$	974,470
Exercisable at June 30, 2021		2,815,568

Stockholders' Equity - Schedule of Changes in Stockholders Equity (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Class Of Stock [Line Items]
Beginning balance	$ 545,873	$ 527,072	$ 247,759	$ 269,881	$ 527,072	$ 269,881
Beginning balance, shares		66,234,056			66,234,056
Issuance of common stock		$ 45,255		5,079
Exercise of stock options	6,163	13,340	1,035	336
Exercise of stock options, shares					1,409,370
Issuance of shares under employee stock purchase plan	970		685
Equity-based compensation	10,614	6,424	4,764	4,157
Other comprehensive income (loss)	(1)	(13)	(218)	112
Net loss	(68,806)	(46,205)	(32,393)	(31,806)	$ (115,011)	(64,199)
Ending balance	$ 494,813	545,873	351,587	247,759	$ 494,813	351,587
Ending balance, shares	68,331,780				68,331,780
Follow-on Offering [Member]
Class Of Stock [Line Items]
Issuance of common stock			107,732
At The Market Offerings [Member]
Class Of Stock [Line Items]
Issuance of common stock			9,643
Regeneron Pharmaceuticals Inc. [Member] \| Private Placement [Member]
Class Of Stock [Line Items]
Issuance of common stock			12,580
Common Stock [Member]
Class Of Stock [Line Items]
Beginning balance	$ 7	$ 7	$ 5	$ 5	$ 7	$ 5
Beginning balance, shares	67,890,334	66,234,056	50,602,875	50,198,044	66,234,056	50,198,044
Issuance of common stock, shares		641,709		351,252
Exercise of stock options, shares	394,801	1,014,569	83,631	53,579
Vesting of restricted units, shares	26,235
Issuance of shares under employee stock purchase plan, shares	20,410		55,296
Ending balance	$ 7	$ 7	$ 6	$ 5	$ 7	$ 6
Ending balance, shares	68,331,780	67,890,334	58,724,238	50,602,875	68,331,780	58,724,238
Common Stock [Member] \| Follow-on Offering [Member]
Class Of Stock [Line Items]
Issuance of common stock			$ 1
Issuance of common stock, shares			6,301,370
Common Stock [Member] \| At The Market Offerings [Member]
Class Of Stock [Line Items]
Issuance of common stock, shares			755,848
Common Stock [Member] \| Regeneron Pharmaceuticals Inc. [Member] \| Private Placement [Member]
Class Of Stock [Line Items]
Issuance of common stock, shares			925,218
Additional Paid-In Capital [Member]
Class Of Stock [Line Items]
Beginning balance	$ 1,027,192	$ 962,173	$ 580,065	$ 570,493	$ 962,173	$ 570,493
Issuance of common stock		45,255		5,079
Exercise of stock options	6,163	13,340	1,035	336
Issuance of shares under employee stock purchase plan	970		685
Equity-based compensation	10,614	6,424	4,764	4,157
Ending balance	1,044,939	1,027,192	716,503	580,065	1,044,939	716,503
Additional Paid-In Capital [Member] \| Follow-on Offering [Member]
Class Of Stock [Line Items]
Issuance of common stock			107,731
Additional Paid-In Capital [Member] \| At The Market Offerings [Member]
Class Of Stock [Line Items]
Issuance of common stock			9,643
Additional Paid-In Capital [Member] \| Regeneron Pharmaceuticals Inc. [Member] \| Private Placement [Member]
Class Of Stock [Line Items]
Issuance of common stock			12,580
Accumulated Other Comprehensive Income (Loss) [Member]
Class Of Stock [Line Items]
Beginning balance	(12)	1	373	261	1	261
Other comprehensive income (loss)	(1)	(13)	(218)	112
Ending balance	(13)	(12)	155	373	(13)	155
Accumulated Deficit [Member]
Class Of Stock [Line Items]
Beginning balance	(481,314)	(435,109)	(332,684)	(300,878)	(435,109)	(300,878)
Net loss	(68,806)	(46,205)	(32,393)	(31,806)
Ending balance	$ (550,120)	$ (481,314)	$ (365,077)	$ (332,684)	$ (550,120)	$ (365,077)

Stockholders' Equity - Schedule of Changes in Stockholders Equity (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020
At The Market Offerings [Member]
Class Of Stock [Line Items]
Stock issuance cost, net	$ 52	$ 23	$ 48
Follow-on Offering [Member]
Class Of Stock [Line Items]
Stock issuance cost, net		$ 369

Subsequent Events

6 Months Ended

Jun. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

13.	Subsequent Events

New CAR-T Cell Therapy Company

On June 22, 2021, the Company announced that it has entered into an agreement with Cellex Cell Professionals GmbH (“Cellex”) and funds managed by Blackstone Life Sciences Advisors L.L.C. (“BXLS”) to establish a new CAR-T cell therapy company (“NewCo”) that will be focused on the development of allogeneic universal CAR-T cell therapies for immuno-oncology and autoimmune diseases. The new company will be headquartered in Cambridge, Massachusetts and will acquire Cellex’s subsidiary GEMoaB GmbH (“GEMoaB”), with established offices and labs in Dresden, Germany. The new company will have an exclusive license to Intellia’s CRISPR/Cas9 allogeneic cell engineering platform limited to its use with GEMoaB’s switchable, universal CAR-T cell platforms (UniCAR and RevCAR). As a subsidiary of the new company, GEMoaB will continue to advance its clinical-stage, autologous CAR-T cell therapy programs. Funds managed by Blackstone Life Sciences have committed up to $250 million to the transaction and with Intellia and Cellex (and certain related entities) have equal ownership of the new company at the time of the initial closing. The transaction closed in the third quarter of 2021.

In July 2021, the new company and Intellia entered into a license and collaboration agreement with NewCo, under which the Company will collaborate to develop allogeneic universal CAR-T cell therapies, as well as a co-development and co-funding (“Co/Co”) agreement to co-develop an allogeneic universal CAR-T cell product for an immuno-oncology indication, which the parties will co-commercialize in the U.S. and key European countries. The Company will have one additional option to enter into a second Co/Co agreement from selected allogeneic universal CAR-T cell therapy products that the parties will develop under the collaboration.

July 2021 Offering

On June 29, 2021, the Company entered into an underwriting agreement related to a public offering of 4,758,620 shares of its common stock (inclusive of shares sold pursuant to the exercise of the underwriters’ option to purchase additional shares) at a public offering price of $145.00 per share. The offering closed on July 2, 2021, for aggregated estimated net proceeds of $648.1 million after deducting $41.9 million in underwriting discounts and estimated offering costs.

New Lease Agreement

In July 2021, the Company entered into an agreement to lease approximately 13,662 square feet of space at 17 Tudor Street in Cambridge, Massachusetts under an operating lease agreement (the “17 Tudor Lease”). The Company’s obligation to pay rent will start on November 1, 2021. The initial term of the 17 Tudor Lease is five years. The Company has an option to extend the 17 Tudor Lease for one three-year term. The base rent under the 17 Tudor Lease is $74.00 per square foot during the first year of the term, which is subject to scheduled annual increases throughout the term, resulting in a base rent of $83.29 per square foot during the last year of the initial term, plus certain operating expenses and taxes.

Commitments and Contingencies - Additional Information (Details) $ in Millions	Jun. 16, 2021 USD ($)
Caribou Leaseback Agreement [Member]
Commitments And Contingencies [Line Items]
Payment related to leaseback	$ 1.0

Leases - Additional Information (Detail) $ in Thousands	1 Months Ended	6 Months Ended
Leases - Additional Information (Detail) $ in Thousands	Mar. 31, 2021 USD ($) USD_per_sqft	Jun. 30, 2021 USD ($) ft²	Dec. 31, 2020 USD ($)
Lessee Lease Description [Line Items]
Operating lease right-of-use assets		$ 77,070	$ 39,114
Albany Lease [Member]
Lessee Lease Description [Line Items]
Area of space leased \| ft²		39,000
Operating lease, description		In March 2020, the Company entered into an agreement to lease approximately 39,000 square feet of office and laboratory space at 281 Albany Street in Cambridge, Massachusetts under an operating lease agreement (the “281 Albany Lease”). The Company’s obligation to pay rent will start on the date that is six months after the commencement date or the date on which the Company occupies the premises, whichever occurs earlier (the “Rent Commencement Date”).
Term of lease		10 years
Base rent per square foot for first year \| USD_per_sqft	99.00
Base rent per square foot for last year \| USD_per_sqft	128.87
Operating lease right-of-use assets	$ 40,400
Operating lease, liability	$ 34,800
Incremental borrowing rate	5.52%
Prepaid lease payments	$ 5,600
Amount receivable on cost of construction and tenant improvement	4,400
Operating lease, existence of option to extend		true
Operating lease, options to extend		The Company has the option to extend the 281 Albany Lease for two successive five-year terms.
Albany Lease [Member] \| Other Assets [Member]
Lessee Lease Description [Line Items]
Letter of credit	$ 1,900